

Claim Amendments:

Claims 1-10 (Cancelled)

Claim 11. (Currently amended): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the patient for each treatment 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient.

Claim 12. (Previously presented): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the patient for each treatment 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof.

Claim 13. (Previously presented): The method of claim 11, comprising administering a dodecasodium salt thereof.

Claim 14. (Previously presented): The method of claim 12, comprising administering a dodecasodium salt thereof.

Claim 15. (Currently amended): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the patient for each treatment 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient.

Claim 16. (Currently amended): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the patient for each treatment 0.30 to 30 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof.

Claim 17. (Previously presented): The method of claim 15, comprising administering a nonasodium salt thereof.

Claim 18. (Previously presented): The method of claim 16, comprising administering a nonasodium salt thereof.

Claim 19. (New): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the circuit for each treatment 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient.

Claim 20. (New): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the circuit for each treatment 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof.

Claim 21. (New): The method of claim 19, comprising administering a dodecasodium salt thereof.

Claim 22. (New): The method of claim 20, comprising administering a dodecasodium salt thereof.

Claim 23. (New): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the circuit for each treatment 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient.

Claim 24. (New): A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising administering to the circuit for each treatment 0.30 to 30 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof.

Claim 25. (New): The method of claim 23, comprising administering a nonasodium salt thereof.

Claim 26. (New): The method of claim 24, comprising administering a nonasodium salt thereof.